Even as Allos Therapeutics Inc. prepares for the commercial launch of Folotyn in relapsed, refractory peripheral T-cell lymphoma following accelerated FDA approval, the Westminster, Colo.-based firm already has its sights set on expanding the targeted antifolate drug into broader the T-cell lymphoma space and other cancer indications. (BioWorld Today) Read More
